Secretion of soluble-form CD93 from human endothelial progenitor cells

ヒト血管内皮前駆細胞(Human endothelial progenitor cells :HEPCs)から分泌される可溶性CD93(sCD93)分子の動態を自主開発した抗ヒトCD93 抗体(mNI-11)を用いて解析した。HEPCs は低濃度であるが、sCD93 分子を培養液中に自然分泌していることがわかった。HEPCs をPKC 活性剤であるPMAで処理したところ、sCD93 分子の分泌は有意に増強した(P < 0.01)。また、PMA 処理の初期段階からsCD93 分泌の増強は認められた。次に、PMA 処理HEPCs にPKC 活性阻害剤であるGo6976 を添加したところ、sCD93 分子の分泌は有意に抑制された(P < 0.01)。一方、HEPCs をアクチンフィラメントの脱重合剤(サイトカラシンE)で処理したところ、sCD93 分子の分泌が有意に増強した(P < 0.01)。HEPCs から分泌されるsCD93 分子は、PKC によるリン酸化とアクチンフィラメントの脱重合が密接に関与していることがわかった。In this study, we examined the secretion of soluble-form CD93 (sCD93) from human endothelial progenitor cells (HEPCs) expressing cell surface CD93 by enzyme-linked immunoassay (EIA) using CD93 monoclonal antibody (mAb) (mNI-11) established in our laboratories. We found that a small amount of sCD93 was spontaneously secreted into the culture supernatants of HEPCs. Furthermore, significantly (P < 0.01) enhanced secretion of sCD93 was found in the culture supernatants of HEPCs treated with phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, which was significantly (P < 0.01) suppressed by treatment of the cells with the protein kinase (PKC) inhibitor Go6976. Interestingly, depolymerization of the actin filaments in the cells by cytochalasin E (CyE) also significantly (P < 0.01) enhanced the sCD93 secretion into the culture supernatants of HEPCs. Taken together, these findings suggest that the sCD93 might serve as a new biomarker for analyzing the biological and immunological functions of HEPCs

Maternal Morbidity in Women with Placenta Previa Managed with Prediction of Morbidly Adherent Placenta by Ultrasonography

Objective. To determine maternal morbidity in women with placenta previa managed with prediction of morbidly adherent placenta (MAP) by ultrasonography. Methods. A retrospective cohort study was undertaken comprising forty-one women who had placenta previa with or without risk factors for MAP. Women who had all three findings (bladder line interruption, placental lacunae, and absence of the retroplacental clear zone) were regarded as high suspicion for MAP and underwent cesarean section followed by hysterectomy. We attempted placental removal for women having two findings or less. Results. Among 28 women with risk, nine with high suspicion underwent hysterectomy and were diagnosed with MAP. Three of 19 women with two findings or less eventually underwent hysterectomy and were diagnosed with MAP. The sensitivity and positive predictive value for the detection of MAP were 64% and 100%. The pathological severity of MAP was significantly correlated with the cumulative number of findings. There were no cases of MAP among 13 women without risk. There was no difference of blood loss between women with high suspicion and those without risk (2186±1438 ml versus 1656±848 ml, resp.; p=0.34). Conclusion. Management with prediction of MAP by ultrasonography is useful for obtaining permissible morbidity